Yahoo
NYSE - Nasdaq Real Time Price USD

Revvity, Inc. (RVTY)

164.93 -0.40 (-0.24%)
As of 10:50:23 AM EDT. Market Open.
Trade Revvity on Coinbase

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Dr. Prahlad R. Singh Ph.D.
CEO, President & Director 3.56M -- 1965
Mr. Maxwell Krakowiak
Senior VP & CFO 1.18M -- 1990
Mr. Tajinder S. Vohra
Senior Vice President of Global Operations 1.03M 195.09k 1966
Mr. Joel S. Goldberg
Senior VP of Administration, General Counsel & Secretary 1.25M 689.38k 1969
Ms. Miriame Victor
Senior Vice President & Chief Business Officer 1.04M -- 1981
Ms. Anita Gonzales
Chief Accounting Officer, VP & Controller -- -- 1976
Mr. Bryan A. Kipp
Senior VP of Technology & Licensing -- -- --
Dr. Madhuri Hegde FACMG, Ph.D.
Senior VP & Chief Scientific Officer -- -- --
Mr. Stephen Barr Willoughby
Senior VP of Investor Relations & Head of ESG -- -- --
Ms. Magali Four
Senior VP and Chief People & Culture Officer -- -- --

Revvity, Inc.

77 4th Avenue
Waltham, MA 02451
United States
781 663 6900 https://www.revvity.com
Sector: 
Healthcare
Full Time Employees: 
11,000

Description

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, and training and services; and instruments, reagents, and assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. It also develops technologies that enable and support genomic workflows using protein coupled receptors and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Revvity, Inc.’s ISS Governance QualityScore as of October 1, 2026 is 6. The pillar scores are Audit: 9; Board: 2; Shareholder Rights: 4; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 3, 2026 at 12:30 PM UTC

Revvity, Inc. Earnings Date

November 13, 2026 at 12:00 AM UTC

Dividend Date

Recent Events

October 23, 2026 at 12:00 AM UTC

Ex-Dividend Date

August 11, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

August 4, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 23, 2026 at 12:00 AM UTC

11-K: Annual report of employee stock purchase

June 1, 2026 at 12:00 AM UTC

SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)

May 12, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

May 5, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 1, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 16, 2026 at 12:00 AM UTC

DEF 14A: Proxy Statements

March 6, 2026 at 12:00 AM UTC

PRE 14A: Proxy Statements

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: